FABP1 and Hepatic steatosis: Ultrasonography, although widely used as a non-invasive diagnostic tool for MASLD, relies on the visual identification of hepatic steatosis and may not capture the full spectrum of liver injury and metabolic dysfunction represented by L-FABP levels [20].